CEO
FINANCIAL HIGHLIGHTS
- Total operating costs have been further reduced to
SEK 4.0 million (Q2/2021:SEK 16.0 million .) This reflects that all resources are now being allocated to our phase IIa study in Tourette - Present funding still expected to cover the remaining cost of the Tourette study
R&D HIGHLIGHTS
TOURETTE SYNDROME
- 70 % of patients have been recruited onto the Tourette study at two sites in
Copenhagen - The dropout rate so far is unexpectedly low, at under 5%. To date no patients have dropped out from our largest 'active dose' group of those patients taking Sepranolone in addition to their regular treatment
-
During summer 2022 we recruited our first teenage patients (at the
Danish National Center for Tourette atHerlev University Hospital )
-
Last-patient-last-visit remains scheduled for
January 2023 - Topline results to be released by the end of Q1 2023
CEO
To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/
For further information, please contact:
Peter Nordkild, CEO
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com
Jakob Dynnes Hansen, CFO
Phone: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com
Certified Adviser
Phone: +46 8-463 83 00
Mail: certifiedadviser@penser.se
ABOUT
We are a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive compulsive disorder that still lack safe, efficacious pharmaceutical treatments.
The information above was provided by the CEO of
https://news.cision.com/asarina-pharma/r/asarina-pharma-ab--publ--q2-2022-report-released,c3619564
https://mb.cision.com/Main/17069/3619564/1618434.pdf
https://mb.cision.com/Public/17069/3619564/a175f2a39658a52f.pdf
(c) 2022 Cision. All rights reserved., source